Peer Review History

Original SubmissionFebruary 4, 2021
Decision Letter - Pasquale Abete, Editor
Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

PONE-D-21-03871

Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study

PLOS ONE

Dear Dr. PONGIGLIONE,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 23 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Pasquale Abete

Academic Editor

PLOS ONE

Additional Editor Comments:

The manuscript is very interesting and topic. However I have only a concern about the importance of HF-related precipitating factors. Please see and discuss Testa G et al. Precipitating factors in younger and older adults with decompensated chronic heart failure: are they different? J Am Geriatr Soc. 2013 Oct;61(10):1827-8.

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for including your ethics statement:  "This study complies with the Declaration of Helsinki. Participation in the ESC-HF-LT-R had been approved by each local institutional review board in accordance with its country’s legislation. All participants provided written informed consent. No data were collected before the patient received detailed information and gave signed informed consent.".   

Please amend your current ethics statement to include the full name of the ethics committee that approved your specific study.

For additional information about PLOS ONE submissions requirements for ethics oversight of animal work, please refer to http://journals.plos.org/plosone/s/submission-guidelines#loc-animal-research  

Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the “Ethics Statement” field of the submission form (via “Edit Submission”).

3.  We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the manuscript entitled Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study, Pongiglione and co-authors report on patient-, hospital- and country-level characteristics associated with 1-year all-cause mortality among patients with chronic HF including geographic and hospital variation in mortality. On 9,277 patients with chronic HF in the prospective cohort study European Society of Cardiology Heart Failure Long Term, the Authors report an all-cause 1-year mortality rate, across 142 hospitals located in 22 countries, of 7.1% which varied between countries and hospitals. These mortality rates were directly associated with increasing age, diabetes, peripheral artery disease, higher NYHA class. Conversely, treatment with angiotensin-converting enzyme inhibitor and angiotensin receptor antagonists and being managed in an HF clinic were found protective against mortality. Interestingly, no other hospital-level characteristics, and no country-level healthcare characteristics were associated with 1-year mortality, suggesting that between-hospital variance might be crucial for HF patients’ outcomes.

Overall, this is a very interesting manuscript on a crucial topic in HF management. The aim is clear, data analysis is well conducted and reported, and results are well discussed. I consider the manuscript acceptable for publication as it stands.

Reviewer #2: The Authors explored hospital and country-level characteristics associated with 1-year all-cause mortality among patients with chronic HF and investigates geographic and hospital variation in mortality. They studied 9,277 patients with chronic HF enrolled between May 2011 and November 2017 in the prospective cohort study European Society of Cardiology Heart Failure Long Term registry across 142 hospitals, located in 22 countries. The mean age of the selected outpatients was 65 years and the all-cause 1- year mortality rate per 100 person-years was 7.1 and varied between countries (median 6.8, IQR 5.6-11.2) and hospitals (median 7.8, IQR 5.2-12.4). Mortality was associated with age (incidence rate ratio 1.03, 95% CI 1.02-1.04), diabetes mellitus (1.37, 1.15-1.63), peripheral artery disease (1.56, 1.27- 1.92), New York Heart Association class III/IV (1.91, 1.60-2.30), treatment with angiotensin-converting enzyme inhibitor and angiotensin receptor antagonists (0.71, 0.57-0.87) and HF clinic (0.64, 0.46-0.89). No other hospital-level characteristics, and no country-level healthcare characteristics were associated with 1-year mortality, with case-mix standardised variance between countries being very low and higher for hospitals (0.372).

I find the study of great interest, data support conclusion even if I suppose a possible role of a selection bias due to the selection made by European Society of Cardiology in the selection of hospital. The involved hospital are of recognize high quality and specifically devoted to cardiovascular disease. This reflect the great Job made the ESC in the diffusion of cardiovascular knowledge all over the Europe.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Francesco CACCIATORE

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Additional Editor Comments:

The manuscript is very interesting and topic. However I have only a concern about the importance of HF-related precipitating factors. Please see and discuss Testa G et al. Precipitating factors in younger and older adults with decompensated chronic heart failure: are they different? J Am Geriatr Soc. 2013 Oct;61(10):1827-8.

Authors: We thank the Associate Editor for this comment. We discussed the importance of HF-related precipitating factors in the discussion and discussed the suggested paper by Testa et al. The paragraph that we added is the following

“The fact that the study design had a mandatory follow-up visit at 12 months to collect information on morbidity and mortality represented a strength and unique opportunity to study survival with a relatively uniform follow-up time across countries. At the same time, however, we had no information on the time course of patients’ HF over this period. Not being able to monitor the HF progress, little we know on possible precipitating factors that may lead to decompensation during the follow-up, and are known to be different in young and older patients (Testa et al., 2013). Nevertheless, we accounted for patients’ clinical and medical history, partly accounting for those factors that may act as precipitators in the HF time course.”

Review Comments to the Author:

Reviewer #1: In the manuscript entitled Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study, Pongiglione and co-authors report on patient-, hospital- and country-level characteristics associated with 1-year all-cause mortality among patients with chronic HF including geographic and hospital variation in mortality. On 9,277 patients with chronic HF in the prospective cohort study European Society of Cardiology Heart Failure Long Term, the Authors report an all-cause 1-year mortality rate, across 142 hospitals located in 22 countries, of 7.1% which varied between countries and hospitals. These mortality rates were directly associated with increasing age, diabetes, peripheral artery disease, higher NYHA class. Conversely, treatment with angiotensin-converting enzyme inhibitor and angiotensin receptor antagonists and being managed in an HF clinic were found protective against mortality. Interestingly, no other hospital-level characteristics, and no country-level healthcare characteristics were associated with 1-year mortality, suggesting that between-hospital variance might be crucial for HF patients’ outcomes.

Overall, this is a very interesting manuscript on a crucial topic in HF management. The aim is clear, data analysis is well conducted and reported, and results are well discussed. I consider the manuscript acceptable for publication as it stands.

Authors: We thank the reviewer very much for her/his positive and supportive feedback.

Reviewer #2: The Authors explored hospital and country-level characteristics associated with 1-year all-cause mortality among patients with chronic HF and investigates geographic and hospital variation in mortality. They studied 9,277 patients with chronic HF enrolled between May 2011 and November 2017 in the prospective cohort study European Society of Cardiology Heart Failure Long Term registry across 142 hospitals, located in 22 countries. The mean age of the selected outpatients was 65 years and the all-cause 1- year mortality rate per 100 person-years was 7.1 and varied between countries (median 6.8, IQR 5.6-11.2) and hospitals (median 7.8, IQR 5.2-12.4). Mortality was associated with age (incidence rate ratio 1.03, 95% CI 1.02-1.04), diabetes mellitus (1.37, 1.15-1.63), peripheral artery disease (1.56, 1.27- 1.92), New York Heart Association class III/IV (1.91, 1.60-2.30), treatment with angiotensin-converting enzyme inhibitor and angiotensin receptor antagonists (0.71, 0.57-0.87) and HF clinic (0.64, 0.46-0.89). No other hospital-level characteristics, and no country-level healthcare characteristics were associated with 1-year mortality, with case-mix standardised variance between countries being very low and higher for hospitals (0.372).

I find the study of great interest, data support conclusion even if I suppose a possible role of a selection bias due to the selection made by European Society of Cardiology in the selection of hospital. The involved hospital are of recognize high quality and specifically devoted to cardiovascular disease. This reflect the great Job made the ESC in the diffusion of cardiovascular knowledge all over the Europe.

Authors: We thank the reviewer very much for her/his positive feedback. We included the comment on the ESC role in selecting hospitals in the discussion in the following paragraph:

(..) Moreover, the fact that the selection of hospitals was made by ESC guarantees a recognized quality of participating hospitals, but at the same time entails a possible selection bias.

References:

Authors: We added the reference

Testa G, Della‐Morte D, Cacciatore F, Gargiulo G, D'Ambrosio D, Galizia G, et al. Precipitating factors in younger and older adults with decompensated chronic heart failure: are they different?. Journal of the American Geriatrics Society. 2013 Oct;61(10):1827-8.

And amended those not compliant with Vancouver form as described in Plos submission guidelines

Attachments
Attachment
Submitted filename: Rebuttal letter.docx
Decision Letter - Pasquale Abete, Editor

Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study

PONE-D-21-03871R1

Dear Dr. PONGIGLIONE,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Pasquale Abete

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

No further comments.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The Authors addressed all the comments form the reviewers. I confirm that the manuscript is acceptable for publication as it stands.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Formally Accepted
Acceptance Letter - Pasquale Abete, Editor

PONE-D-21-03871R1

Patient, hospital and country-level risk factors of all-cause mortality among patients with chronic heart failure: Prospective international cohort study

Dear Dr. Pongiglione:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Pasquale Abete

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .